The FDA's movement to encourage real-world data use through downstream acceptance is, in effect, a call to action for sponsors to begin exploring — if they haven't already — how to use it upstream as ...

Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.

GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership ...

As GLP-1 competition shifts from molecules to prescriptions, manufacturers, pharmacies, providers, and payers are racing to ...

FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon ...

A key factor of this is the growing acceptance of RWD in trial design. The agency hopes that by allowing RWD collected by ...

Novo teams up with Anthropic on AI-driven drug discovery, Sling Therapeutics and Circle Pharma close major financing rounds, ...

Orbis Medicines announced a strategic collaboration and license agreement with Novo to discover and develop next-generation ...

FDA approved KERENDIA (finerenone) as the first new treatment in 30 years for adults with chronic kidney disease associated ...

Elaine Ferguson, global president at Inizio Medical, spoke with Pharmaceutical Executive about the importance of both managing and growing talent. In today’s world, this requires people already in ...